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Every year ~230 million adults around the world undergo major 
non-cardiac surgery.[1] The Vascular Events in Noncardiac Surgery 
Patients Cohort Evaluation (VISION) study highlighted the incidence 
of perioperative cardiac complications in patients with cardiovascular 
comorbidities. The findings showed that in patients aged ≥45 years, 
the 30-day mortality rate was 2%,[2] and 8% had significant myocardial 
injury that contributed to subsequent morbidity.[3]
Current guidelines emphasise the need to identify high-risk non-
cardiac surgical patients through preoperative risk stratification. [4] 
However, widely used clinical risk stratification tools such as the 
Revised Cardiac Risk Index (RCRI) do not perform as well as 
cardiovascular biomarkers, specifically natriuretic peptides (NPs). [5] 
Raised preoperative B-type NPs have a strong association with 
postoperative cardiac complications. This has been shown in 
observational studies and meta-analyses, and has been the impetus 
for including B-type NP screening for high-risk surgical patients.[6,7]
Some preoperative international guidelines, such as the 
Canadian Cardiovascular Society (CCS) guidelines on perioperative 
cardiovascular risk assessment, advocate that all patients aged 
≥45  years who have ‘significant cardiovascular disease’ and present 
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Background. International guidelines recommend risk stratification to identify high-risk non-cardiac surgical patients. It is also recommended 
that all patients aged ≥45 years with significant cardiovascular disease should have preoperative natriuretic peptide (NP) testing. Abnormal 
preoperative B-type NPs have a strong association with postoperative cardiac complications. In South African hospitals, it is not known how 
many patients with significant cardiovascular disease scheduled for intermediate- to high-risk surgery will have raised NPs.
Objectives. To determine the prevalence of abnormal (raised) NPs in non-cardiac surgical patients with cardiac clinical risk factors. 
A secondary objective was to develop a model to identify surgical patients who may benefit from preoperative NP screening.
Methods. The inclusion criteria were patients aged ≥45 years presenting for elective, non-obstetric, intermediate- to high-risk non-cardiac 
surgery with at least one of the following cardiovascular risk factors: a history of ischaemic heart disease or peripheral vascular disease 
(coronary equivalent); a history of stroke or transient ischaemic attack; a history of congestive cardiac failure; diabetes mellitus currently on 
an oral hypoglycaemic agent or insulin; and serum creatinine level >175 µmol/L (>2.0 mg/dL). Blood samples for N-terminal-prohormone 
B-type NP (NT-proBNP) were collected before induction of anaesthesia. The preoperative prognostic threshold for abnormal (raised) 
NT-proBNP was ≥300 pg/mL. A generalised linear mixed model was used to determine the association between the risk factors and an 
abnormal NT-proBNP level.
Results. Of 172 patients, 63 (37%) had an elevated preoperative NT-proBNP level. The comorbidities independently associated with 
elevated preoperative NT-proBNP were coronary artery disease or peripheral vascular disease, congestive cardiac failure, diabetes mellitus, 
and a creatinine level >175 µmol/L.
Conclusions. We strongly recommend that non-cardiac surgical patients aged ≥45 years undergoing intermediate- or high-risk non-
cardiac surgery with a history of coronary artery disease/peripheral vascular disease, congestive cardiac failure, diabetes mellitus or elevated 
creatinine have preoperative NP testing as part of risk stratification.
S Afr Med J 2021;111(4):338-342. https://doi.org/10.7196/SAMJ.2021.v111i4.15226
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for intermediate- to high-risk surgery should have preoperative NP 
testing.[4] ‘Significant cardiovascular disease’ is defined as a history 
of coronary artery disease, cerebrovascular disease, peripheral artery 
disease, congestive heart failure or severe pulmonary hypertension, 
or a severe obstructive intracardiac abnormality (severe aortic 
stenosis, severe mitral stenosis, or severe hypertrophic obstructive 
cardiomyopathy).[4]
The rationale for the present study was that in the South African 
(SA) context, it is unknown how many patients with significant 
cardiovascular disease scheduled for intermediate- to high-risk 
surgery will have raised NPs. This information is necessary to inform 
appropriate preoperative screening protocols for patients at risk of 
cardiovascular events following non-cardiac surgery. Indiscriminate 
preoperative NP testing would be inappropriate in a resource-
limited environment. A data-informed approach to preoperative NP 
screening may reduce costs and focus efforts on those patients at 
greatest cardiovascular risk in the perioperative period.
Objectives
To describe the prevalence of and associations with abnormal (raised) 
NPs in patients with clinical risk factors for cardiovascular disease 
undergoing intermediate- and high-risk surgery.
Methods
This was a prospective, observational study conducted in seven 
public sector hospitals in Western Cape Province, SA. Paarl, Victoria, 
Mitchells Plain, George, Worcester and New Somerset hospitals are 
secondary-level hospitals and Groote Schuur Hospital is a tertiary-
level hospital. Ethics approval was provided by the Human Research 
Ethics Committee of the Faculty of Health Sciences of the University 
of Cape Town (ref. no. 463/2019) and the trial was registered on 
ClinicalTrials.gov (ref. no. NCT 04114032). Approval was granted by 
the Western Cape Department of Health and the individual hospitals 
to conduct the study (provincial approval ref. no. WC_201909_006).
The primary objective was to determine the prevalence of abnormal 
(raised) NP levels in patients with clinical risk criteria. Abnormal 
(raised) NP levels were defined according to the NP thresholds 
associated with major adverse cardiac events following non-cardiac 
surgery, with an N-terminal-prohormone B-type NP (NT-proBNP) 
level >300 ng/L.[6] The secondary objective was to develop a model 
to identify surgical patients who may benefit from preoperative 
NP screening. The inclusion criteria were patients aged ≥45 years 
presenting for elective, non-obstetric, intermediate- to high-risk non-
cardiac surgery with at least one of the following cardiovascular risk 
factors: a history of ischaemic heart disease or peripheral vascular 
disease (coronary equivalent); a history of stroke or transient ischaemic 
attack; a history of congestive cardiac failure; diabetes mellitus 
currently on an oral hypoglycaemic agent or insulin; and serum 
creatinine level >175 µmol/L (>2.0 mg/dL). Intermediate-risk surgery 
is defined as having a 30-day risk of cardiovascular death or non-fatal 
myocardial infarction of 1 - 5%, and high-risk surgery as exceeding 
5%.[8] Emergency and day-case surgery were excluded. Patients were 
screened on the afternoon before surgery and provided written 
informed consent during preoperative anaesthesia assessment. Baseline 
demographic and clinical data included age, gender, preoperative 
haemoglobin, white cell count and serum creatinine. If a preoperative 
electrocardiogram was done, a copy was kept as a source document.
Blood samples for NT-proBNP testing were collected in theatre 
before induction of anaesthesia on insertion of the intravenous 
cannula for vascular access. The specimens were couriered to 
PathCare Laboratories and analysed within 2 hours of the blood 
specimen being drawn. The team in theatre were blinded to the 
NT-proBNP result, since this was only available postoperatively. 
However, elevated NT-proBNP results that were of prognostic 
importance for postoperative cardiovascular events were declared 
to the surgeons postoperatively, and they were advised to do 
troponin screening for 3 days. The reporting of results to surgeons 
postoperatively would allow for institution of supportive strategies 
(e.g. management of tachycardia,[9] optimisation of haemoglobin 
if necessary,[10] administration of aspirin and statin therapy)[11] and 
monitoring for progression to myocardial infarction, and cardio-
vascular risk modification could be advocated following discharge.
In order to evaluate the association between five clinical risk 
factors and an abnormal (raised) NT-proBNP level in a binary logistic 
regression model, a sample that included at least 50 patients with an 
abnormal level would be required. To ensure that we fulfilled this 
requirement, we estimated the sampling cohort as follows. Based 
on previous observational studies in the Western Cape, we expected 
to screen ~800 elective surgical patients in all centres over a 4-week 
period, of whom we expected that 160 would fulfil clinical and 
surgical criteria for NP testing, and that of these ~65 would have 
abnormal (raised) NPs. The sample size was derived on an estimated 
prevalence of a raised NP level of 40% (95% confidence interval 
(CI)  33 - 48). Sixty-five patients with raised NPs would provide 
sufficient power to allow for a regression that included the five 
clinical risk factors of the RCRI, and would not violate the 10 events 
(raised NPs) per variable rule.[12]
A generalised linear mixed model using a logit link was used to 
identify independent risk factors for the binary outcome. These 
included a one-level and a hierarchical two-level model to account for 
the expected correlation in outcomes within hospitals. We excluded 
patients with missing values for potential risk predictors, and only 
used complete case analysis as <1% of the dataset was incomplete for a 
potential clinical risk predictor.[13] Results are reported as adjusted odds 
ratios with 95% CIs. All the RCRI factors were entered into the models, 
with the exception of the type of surgery, as all patients were scheduled 
for intermediate- or high-risk surgery. The potential independent 
predictors entered into the model were a history of ischaemic heart 
disease or peripheral vascular disease (coronary equivalent); a history 
of stroke or transient ischaemic attack; a history of congestive cardiac 
failure; diabetes mellitus currently on an oral hypoglycaemic agent or 
insulin; and serum creatinine level >175  µmol/L (>2.0 mg/dL). The 
independent variables associated with an abnormal NP level would 
be used to build a model to predict which patients should undergo 
preoperative NP testing prior to intermediate or major surgery.
Continuous data are reported as mean and standard deviation (SD) 
or median and interquartile range, and categorical data as number 
and percentage. The Statistical Package for the Social Sciences version 
24 (SPSS Inc., USA) was used for data analysis.
Results
The patients recruited into the study are shown in the STROBE 
(Strengthening the Reporting of Observational Studies in 
Epidemiology) diagram in Fig. 1. The trial was extended to 8 
consecutive weeks in each hospital over the months beginning 
October 2019 to end of March 2020 in order to reach the sample 
size required for the study. The study was stopped because of the 
curtailment of elective surgery during the COVID-19 pandemic 
lockdown, with 63/172 patients (37%) with an abnormal (raised) 
NT-proBNP level, 2 patients fewer than our target. The baseline 
patient characteristics are set out in Table 1.
Only one preoperative creatinine value was missing from the 
data set, since no renal function test was done for the patient 
preoperatively.
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The prevalence of abnormal (raised) NT-proBNP in patients with 
clinical risk criteria was 37%. Table 2 shows recruitment across the 
study sites. The highest recruiting sites were Groote Schuur, Paarl 
and Victoria hospitals.
The comorbidities that were independently associated with 
elevated NT-proBNP in the generalised linear mixed model were 
coronary artery disease (and coronary equivalent, peripheral vascular 
disease), congestive cardiac failure, diabetes mellitus and a creatinine 
level >175 µmol/L (Table 3).
The preoperative risk calculator (Table 4) shows that the presence 
of diabetes mellitus is associated with a 13% probability of a 
high NT-proBNP level, coronary artery disease/peripheral vascular 
disease with an 18% probability, congestive cardiac failure with a 
28% probability and elevated creatinine with a 43% probability. The 
Patients screened,
N=3 638 (GSH n=1 275, 
other hospitals n=2 363)




n= 200 (6%) (GSH n=99, 
other hospitals n=101)
Not consented, n=20:
• Consent not taken, n=12
• Dementia, n=2
• Refused consent, n=4




• Paarl Hospital, n=27
• Worcester Hospital, n=11
• Victoria Hospital, n=30
• New Somerset Hospital, n=7
• Mitchells Plain Hospital, n=7







• Blood samples not fetched 
 by courier, n=4
• Delayed analysis of 
 blood samples, n=2
• Blood sampling missed, 
 n=2
Fig. 1. STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) diagram. (NT-proBNP = N-terminal-prohormone B-type natriuretic 
peptide; GSH = Groote Schuur Hospital.)
Table 1. Baseline characteristics of patients
Whole cohort  
(N=172)
High NT-proBNP*  
(N=63; 37%) 
Normal NT-proBNP  
(N=109; 63%) p-value
Age (years), mean (SD) 63.5 (9.8) 65.4 (10.2) 62.4 (9.4) 0.0523
Gender female, n (%) 92 (54) 28 (44) 64 (59) 0.0423
Comorbidity, n (%)
CAD/PVD 76 (44) 33 (52) 43 (39) 0.1087
CCF 24 (14) 14 (22) 10 (9) 0.2182
Diabetes mellitus 97 (56) 35 (56) 62 (57) 0.8886
Stroke/TIA 18 (10.5) 3 (5) 15 (14) 0.3639
Creatinine >175 µmol/L 15 (8.7) 10 (16) 5 (5) 0.3340
NT-proBNP = N-terminal-prohormone B-type natriuretic peptide; SD = standard deviation; CAD/PVD = coronary artery disease/peripheral vascular disease; CCF = congestive cardiac failure; 
TIA = transient ischaemic attack.
*High NT-proBNP >300 ng/L.
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baseline probability in the cohort is 6%. The risk equation to derive 
the probability of high NT-proBNP appears alongside, below Table 4. 
Discussion
The main finding of this study was that of SA patients aged 
≥45 years with clinical cardiovascular risk factors scheduled for 
intermediate- or high-risk non-cardiac surgery, 1 in 3 will have 
an abnormal (raised) NT-proBNP level. In addition, patients with 
a history of coronary artery disease/peripheral vascular disease 
or congestive cardiac failure or a creatinine level >175 µmol/L 
have a >15% probability of a high preoperative NT-proBNP 
level. Patients with diabetes mellitus have a 13% probability of 
a high NT-proBNP level. Previous studies have shown that high 
preoperative NPs are prognostic of perioperative cardiovascular 
complications.
Study strengths and limitations
The strengths of this study are that it was a prospective, pragmatic 
study, which provides information for preoperative risk stratification 
of SA surgical patients scheduled for intermediate- and high-risk 
non-cardiac surgery. In the SA resource-limited environment, these 
findings suggest that it is justifiable to conduct preoperative NP 
testing in patients with coronary artery disease/peripheral vascular 
disease, congestive cardiac failure, diabetes mellitus and an elevated 
creatinine level scheduled for intermediate- and high-risk surgery. 
 Since we recruited patients who already had at least one of the RCRI 
risk factors, this patient cohort represents a high-risk group. The 
high risk of the patient cohort explains the baseline probability of an 
elevated NP level in the cohort of 6%.
A further strength of this study is that it was a multicentre 
study that included hospitals serving different demographic areas. 
Controlling for the hospital clusters suggests that the findings 
are robust and generalisable to patients from different healthcare 
facilities in the Western Cape. Furthermore, controlling for the 
clusters may explain the difference between the lack of association of 
diabetes mellitus with an abnormal NT-proBNP level on univariate 
analysis, but not on multivariate analysis.
The weakness of the study is that we did not follow up these patients 
for cardiovascular outcomes. However, a large observational cohort 
study suggests that an abnormal (raised) preoperative NP level is an 
important independent predictor of postoperative cardiovascular 
Table 2. Patient recruitment characteristics per hospital
Hospital
Patients for elective 
surgery, N
Patients fulfilling study inclusion 
criteria (RCRI ≥1), n (%)
Raised NT-proBNP, 
n (%)
No consent, no blood 
sample taken, n
Groote Schuur 1 275 99 (8) 33 (33) 13
Paarl 431 27 (6) 10 (37) 0
Worcester 264 12 (5) 1 (8) 1
Victoria 483 37 (8) 11 (30) 6
New Somerset 486 13 (3) 2 (15) 4
Mitchells Plain 206 2 (1) 0 0
George 493 10 (2) 6 (60) 1
RCRI = Revised Cardiac Risk Index; NT-proBNP = N-terminal-prohormone B-type natriuretic peptide.
Table 3. Multivariable association with a prognostically important elevated NT-proBNP
Comorbidities (predictors) p-value OR 95% CI
CAD/PVD 0.006 3.333 1.426 - 7.787
CCF 0.001 5.984 2.040 - 17.553
Stroke/TIA 0.069 0.232 0.048 - 1.123
Diabetes 0.045 2.369 1.021 - 5.494
Creatinine >175 µmol/L 0.001 11.459 2.889 - 45.454
NT-proBNP = N-terminal-prohormone B-type natriuretic peptide; OR = odds ratio: CI = confidence interval; CAD/PVD = coronary artery disease/peripheral vascular disease;  
CCF = congestive cardiac failure; TIA = transient ischaemic attack.
Table 4. Preoperative risk calculator




Diabetes mellitus 0.8621 13
Creatinine >175 µmol/L 2.439 43
NT-proBNP = N-terminal-prohormone B-type natriuretic peptide; CAD/PVD = coronary artery disease/peripheral vascular disease; CCF = congestive cardiac failure.
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morbidity and mortality.[14] We therefore believe that our findings are 
of clinical relevance in preoperative cardiovascular risk stratification 
in SA.
Studies have also shown that the addition of NP testing to 
existing clinical risk indices, such as the RCRI, improves prognostic 
performance. However, clinical risk factors are not equally weighted 
and some clinical risk factors may have a greater impact on patient 
outcomes. In our study, four of the five traditional preoperative 
cardiovascular risk factors, coronary artery disease/peripheral 
vascular disease, congestive cardiac failure, diabetes mellitus and 
elevated creatinine, were found to be independently associated 
with NP elevation. This study supports the CCS guidelines in using 
clinical risk predictors as a screening tool to identify which patients 
should have preoperative NP screening.
The cardiovascular disease burden per site in Table 2 can be used 
to plan for resource allocation and funding for NT-proBNP screening 
in high-risk patients.
Recommendations
Our recommendation is that surgical patients scheduled for 
intermediate- and high-risk non-cardiac surgery with a history 
of coronary artery disease/peripheral vascular disease, congestive 
cardiac failure, diabetes mellitus or an elevated creatinine level 
should have preoperative NP testing done. We recommend that 
patients with an abnormal (raised) NT-proBNP level should also have 
postoperative troponin screening. Patients with a normal level do 
not require additional postoperative monitoring for cardiovascular 
events.[4] Given that the baseline probability of elevated NPs was 6%, 
we recommend that patients with a history of stroke should also have 
preoperative NT-proBNP screening, and postoperative troponin 
screening if the NT-proBNP level is abnormal. Finally, the small 
number of patients with a history of stroke or transient ischaemic 
attack would suggest that a larger study is required in order to 
determine whether a history of stroke or transient ischaemic attack 
is independently associated with an abnormal (raised) NT-proBNP 
level. Furthermore, the role of NT-proBNP screening on the basis of 
age alone remains uncertain in SA, where further research is needed. 
To understand the full implications of these findings for clinical 
practice in SA, a cost-effectiveness analysis would be beneficial.
Future research should focus on preoperative optimisation of 
patients with elevated NPs.
Conclusions
We recommend that SA surgical patients scheduled for intermediate- 
and high-risk non-cardiac surgery with a history of coronary 
artery disease/peripheral vascular disease, congestive cardiac failure, 
diabetes mellitus or an elevated creatinine level have preoperative 
natriuretic testing done as part of risk stratification. We suggest that if 
these surgical patients have a history of stroke or transient ischaemic 
attack, they may also benefit from preoperative natriuretic testing. 
Patients with an abnormal (raised) NT-proBNP level should have 
postoperative troponin screening.
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